Our top pick for
Check-Cap Ltd is a diagnostics & research business based in the US. Check-Cap shares (CHEK) are listed on the NASDAQ and all prices are listed in US Dollars. Check-Cap employs 64 staff and has a market cap (total outstanding shares value) of USD$66.6 million.
|52-week range||USD$0.243 - USD$2.39|
|50-day moving average||USD$1.6955|
|200-day moving average||USD$0.7398|
|Wall St. target price||USD$1.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.889|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-47.97%|
|Return on equity TTM||-91.32%|
|Market capitalisation||USD$66.6 million|
TTM: trailing 12 months
There are currently 3.4 million Check-Cap shares held short by investors – that's known as Check-Cap's "short interest". This figure is 27.8% up from 2.7 million last month.
There are a few different ways that this level of interest in shorting Check-Cap shares can be evaluated.
Check-Cap's "short interest ratio" (SIR) is the quantity of Check-Cap shares currently shorted divided by the average quantity of Check-Cap shares traded daily (recently around 10.8 million). Check-Cap's SIR currently stands at 0.32. In other words for every 100,000 Check-Cap shares traded daily on the market, roughly 320 shares are currently held short.
However Check-Cap's short interest can also be evaluated against the total number of Check-Cap shares, or, against the total number of tradable Check-Cap shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Check-Cap's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Check-Cap shares in existence, roughly 70 shares are currently held short) or 0.0747% of the tradable shares (for every 100,000 tradable Check-Cap shares, roughly 75 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Check-Cap.
Find out more about how you can short Check-Cap stock.
We're not expecting Check-Cap to pay a dividend over the next 12 months.
Check-Cap's shares were split on a 1:12 basis on 4 April 2018. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Check-Cap shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Check-Cap shares which in turn could have impacted Check-Cap's share price.
Over the last 12 months, Check-Cap's shares have ranged in value from as little as $0.243 up to $2.39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Check-Cap's is 0.1387. This would suggest that Check-Cap's shares are less volatile than average (for this exchange).
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. The company was founded in 2004 and is based in Isfiya, Israel.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.